Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 102)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lumefantrine |
Approved |
Phase 4 |
|
82186-77-4 |
6437380 |
Synonyms:
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-a-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
(+-)-2,7-dichloro-9-((Z)-P-Chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
(±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol
120583-69-9
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl]ethanol
2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
2-dibutylamino-1-[2,7-dichloro-9-(4-chloro-Benzylidene)-9H-fluoren-4-yl]-ethanol
2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol
2-dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol
82186-77-4
AC1O5NKD
AC-4542
benflumetol
Benflumetol
Benflumetol, (-)-isomer
Benflumetol, (+)-isomer
|
Benflumetol, (+-)-isomer
Bio-0132
C30H32Cl3NO
CHEBI:156095
CHEMBL38827
CID6437380
Coartem
D03821
DB06708
dl-Benflumelol
DL-Benflumelol
HSDB 7210
I14-7746
LS-177674
Lumefantrine
Lumefantrine (INN)
Lumefantrine [INN:BAN]
MolPort-006-394-826
NCGC00167490-01
UNII-F38R0JR742
|
|
2 |
|
Artemether |
Approved |
Phase 4 |
|
71963-77-4 |
68911 9796294 119380 |
Synonyms:
( )-alpha-Artemether
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12aR*)-isomer of artemether
(3r,5as,6r,8as,9r,10r,12r,12ar)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin
(5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene
.beta.-Artemether
.beta.-Dihydroartemisinin methyl ether
.beta.-Methylether of 11-epi-dihydroartemisinin
10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
159573-83-8
3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-tri
71939-51-0
71963-77-4
74784-06-8
80286-56-2
93787-85-0
AC1L2APD
AC1L2XO8
AC1L9SH2
AC1L9UV0
AC1MI2ZX
AC1Q6Z74
AC1Q6Z7V
alpha-Artemether
alpha-Dihydroartemisinin methyl ether
AR-1A4424
Arteannuin ether
Artemetero
Artemetero [INN-Spanish]
Artemether
Artemether (INN)
Artemether [INN]
artemether, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-isomer
artemether[inn]
Artemetheri
Artemetherum
Artemetherum [INN-Latin]
Artemisininelactol methyl ether
Artemos
Artenam
Artesaph
Artesian
Artimist
Artmether
b-Artemether
b-Dihydroartemisinin methyl ether
beta-Artemether
|
beta-Dihydroartemisinin methyl ether
BRN 5948416
C16H26O5
CHEBI:195280
CHEMBL411864
CHEMBL512315
CID10266705
CID104888
CID3062122
CID456408
CID500199
CID6483308
CID6712286
CID68911
CID9796294
CID9796295
CPD000469218
D02483
DB06697
dihydroartemisinin methyl ether
Dihydroartemisinin methyl ether
Dihydroqinghaosu methyl ether
Dihydroquinghaosu methyl ether
Falcidol
Gvither
HMS2052L09
HSDB 7456
I06-0205
KST-1A8041
LS-176935
LS-64237
Malartem
methyl-dihydroartemisinine
Methyl-dihydroartemisinine
MLS001424249
NCI60_022891
NSC 665970
NSC665970
O-Methyldihydroartemisinine
Paluther
rither
S2264_Selleck
SAM001246799
SM 224
SM 229
SM-224
SMR000469218
UNII-C7D6T3H22J
β-artemether
β-dihydroartemisinin methyl ether
|
|
3 |
|
Artemether, Lumefantrine Drug Combination |
|
Phase 4 |
|
|
|
4 |
|
Iron |
Approved, Experimental |
Phase 3 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
5 |
|
Albendazole |
Approved, Vet_approved |
Phase 3 |
|
54965-21-8 |
2082 |
Synonyms:
((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle
((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]
(5-(propylthio)-1H-Benzimidazol-2-yl)carbamate methyl ester
(5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-(propylthio)-1H-Benzimidazol-2-yl)carbamic acid methyl ester
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester
[5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester
[5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester
5-(propylthio)-2-carbomethoxyaminobenzimidazole
5-(propylthio)-2-Carbomethoxyaminobenzimidazole
5-(Propylthio)-2-carbomethoxyaminobenzimidazole
54965-21-8
A4673_FLUKA
A4673_SIGMA
AB00052377
AC-015
AC1L1CVL
AC1Q2YKD
AKOS000540882
Albendazol
Albendazol [INN-Spanish]
albendazole
Albendazole
Albendazole (JAN/USP/INN)
Albendazole [USAN:INN:BAN:JAN]
Albendazole armstrong brand
Albendazole Armstrong Brand
Albendazole diba brand
Albendazole Diba Brand
Albendazole fustery brand
Albendazole Fustery Brand
Albendazole hormona brand
Albendazole Hormona Brand
Albendazole liferpal brand
Albendazole Liferpal Brand
Albendazole monohydrochloride
Albendazole Monohydrochloride
Albendazole Noe-Socopharm Brand
Albendazole noé-socopharm brand
Albendazole pfizer brand
Albendazole Pfizer Brand
Albendazole sanicoopa brand
Albendazole Sanicoopa Brand
Albendazole valdecasas brand
Albendazole Valdecasas Brand
Albendazolum
Albendazolum [INN-Latin]
Albendoral
Albenza
Albenza (TN)
Albenza, Eskazole, Zentel, Andazol, Albendazole
Armstrong brand OF albendazole
Armstrong Brand of Albendazole
BAS 00439961
BB_SC-1386
Bendapar
BIDD:GT0615
Bilutac
BIM-0051849.0001
BPBio1_000038
BRD-K79131256-001-04-7
BSPBio_000034
BSPBio_002548
C01779
CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER
Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester
CAS-54965-21-8
CHEBI:16664
CHEBI:506787
CHEMBL1483
ChemDiv1_000190
ChemDivAM_000003
CID2082
CPD000036735
D00134
D015766
DB00518
Diba brand OF albendazole
Diba Brand of Albendazole
Digezanol
Disthelm
Disthelm, mediamix V
Disthelm, Mediamix V
DivK1c_000704
EINECS 259-414-7
Endoplus
Eskazole
Fustery brand OF albendazole
Fustery Brand of Albendazole
Gascop
HMS1568B16
HMS1922K04
HMS2090G19
HMS2093K13
HMS502D06
HMS587I14
Hormona brand OF albendazole
|
Hormona Brand of Albendazole
HSDB 7444
I01-0380
IDI1_000704
InChI=1/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
KBio1_000704
KBio2_002012
KBio2_004580
KBio2_007148
KBioGR_000801
KBioSS_002012
Liferpal brand OF albendazole
Liferpal Brand of Albendazole
LS-50618
Lurdex
Mediamix V disthelm
Mediamix V Disthelm
methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate
methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate
methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate
Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate
methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate
Methyl 5-(propylthio)-2-benzimidazolecarbamate
Methyl 5-(propyl-thio)-2-benzimidazolecarbamate
methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate
Methyl-5-[propylthio]-2-benzimidazole carbamate
Metiazol
MLS000069722
MolPort-000-726-929
MolPort-000-760-571
MolPort-001-932-918
Monohydrochloride, albendazole
Monohydrochloride, Albendazole
NCGC00016876-01
NCGC00016876-02
NCGC00022896-03
NCGC00022896-04
NCGC00022896-05
NCGC00022896-06
NCGC00022896-07
NINDS_000704
Noe Socopharm Brand of Albendazole
Noé socopharm brand OF albendazole
Noe-Socopharm Brand of Albendazole
Noé-socopharm brand OF albendazole
NSC 220008
NSC220008
O-methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamic acid
Oprea1_429292
Oprea1_585016
Oprea1_640007
Pfizer brand OF albendazole
Pfizer Brand of Albendazole
Prestwick_675
Prestwick0_000247
Prestwick1_000247
Prestwick2_000247
Prestwick3_000247
Proftril
S1640_Selleck
SAM002589939
Sanicoopa brand OF albendazole
Sanicoopa Brand of Albendazole
SK And F 62979
SK And F62979
SK And F-62979
SK&F 62979
SK&F62979
SK&F-62979
SKF 62979
SKF62979
SKF-62979
Smith Kline & French Brand of Albendazole
SmithKline beecham brand OF albendazole
SmithKline Beecham Brand of Albendazole
SMR000036735
SPBio_002253
Spectrum_001532
SPECTRUM1503903
Spectrum4_000201
Spectrum5_001567
STK387550
STL046130
STOCK2S-67946
TL8003543
UNII-F4216019LN
V Disthelm, mediamix
V Disthelm, Mediamix
Valbazen
Valdecasas brand OF albendazole
Valdecasas Brand of Albendazole
VU0239747-6
Zental
Zentel
ZINC17146904
|
|
6 |
|
Sulfadoxine |
Approved, Investigational |
Phase 3 |
|
2447-57-6 |
17134 |
Synonyms:
2447-57-6
46810_RIEDEL
4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide
4-Sulfanilamido-5,6-dimethoxypyrimidine
4-Sulphanilamido-5,6-dimethoxypyrimidine
5-25-13-00306 (Beilstein Handbook Reference)
6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine
AB00514044
AC-11921
AC1L29DT
AC1Q46GG
Ambap2447-57-6
BPBio1_001286
BRD-K55250441-001-03-1
BRN 0625453
BSPBio_001168
C07630
CAS-2447-57-6
CHEBI:9329
CHEMBL1539
CID17134
D00580
DB01299
EINECS 219-504-9
Fanasil
Fanzil
HMS1571K10
HMS2090P07
HMS2094C19
I09-0529
LS-31247
MLS002154150
MolPort-003-850-341
N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide
N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide
NCGC00016612-01
NCGC00016612-02
|
Orthosulfin
Prestwick0_001094
Prestwick1_001094
Prestwick2_001094
Prestwick3_001094
Ro 4-4393
Ro-4-4393
Roche brand OF sulfadoxine
S2511_Selleck
S7821_SIGMA
Sanasil: Sulfadoxine: Sulformetoxin
SMR000857259
Solfadossina
Solfadossina [DCIT]
SPBio_003054
Sulfadoxin
Sulfadoxina
Sulfadoxina [INN-Spanish]
Sulfadoxine
SULFADOXINE
Sulfadoxine (JAN/USP/INN)
Sulfadoxine [USAN:INN:BAN:JAN]
Sulfadoxine roche brand
Sulfadoxinum
Sulfadoxinum [INN-Latin]
Sulformethoxine
Sulformetoxine
Sulforthomidine
Sulphadoxina
Sulphadoxine
Sulphadoxinum
Sulphormethoxine
Sulphormetoxin
Sulphorthodimethoxine
Sulphorthomidine
UNII-88463U4SM5
WR 4073
WR 4873
ZINC00002094
|
|
7 |
|
Pyrimethamine |
Approved, Investigational, Vet_approved |
Phase 3 |
|
58-14-0 |
4993 |
Synonyms:
2,4-diamino-5-(4-Chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(4-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-(P-Chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(p-chlorophenyl)-6-ethylpyrimidine
2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
2,4-diamino-5-Chlorophenyl-6-ethylpyrimidine
2,4-Diamino-5-chlorophenyl-6-ethylpyrimidine
46706_FLUKA
46706_RIEDEL
4753 r.p
4753 R.P.
5-(4-chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4'-Chlorophenyl)-2,4-diamino-6-ethylpyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidi nediamine
5-(4-Chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
5-(4-CHLOROPHENYL)-6-ETHYL-2,4-PYRIMIDINEDIAMINE
5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine
5-(4-CHLORO-PHENYL)-6-ETHYL-PYRIMIDINE-2,4-DIAMINE
5-(p-chlorophenyl)-6-ethyl-2,4-diaminopyrimidine
5-[4-Chlorophenyl]-6-ethyl-2,4-pyrimidinediamine
58-14-0
AB00052084
AC1L1JDI
AC-7879
AI3-25005
Aventis brand OF pyrimethamine
Aventis Brand of Pyrimethamine
AZT + Pyrimethamine combination
BIDD:GT0149
BIDD:PXR0173
BPBio1_000147
BRD-K88429204-001-05-4
BRN 0219864
BSPBio_000133
BSPBio_003282
BW 5063
BW 50-63
C07391
C12H13ClN4
CAS-58-14-0
CCRIS 546
CD
CHEBI:8673
CHEMBL36
Chloridin
Chloridine
Chloridyn
CID4993
CP6
CPD000058714
CRL-8131 & Pyrimethamine
CRL-8142 & Pyrimethamine
D00488
D011739
Darachlor
Daraclor
Darapram
Daraprim
Daraprim (TN)
Daraprime
Daraprin
DB00205
Diaminopyritamin
Disulone
DivK1c_000652
EINECS 200-364-2
Erbaprelina
Ethylpyrimidine
EXR-101
Fansidar
Fansidar (Pyrimethamine/Sulfadoxine)
glaxo Wellcome brand OF pyrimethamine
Glaxo Wellcome Brand of Pyrimethamine
GlaxoSmithKline brand OF pyrimethamine
GlaxoSmithKline Brand of Pyrimethamine
HMS1568G15
HMS1920N12
HMS2092E13
HMS502A14
IDI1_000652
KBio1_000652
KBio2_001386
|
KBio2_003954
KBio2_006522
KBio3_002502
KBioGR_001007
KBioSS_001386
Khloridin
L000713
Lactoferrin B & Pyrimethamine
Lactoferrin H & Pyrimethamine
LS-238
m alocid
Malacid
Malocid
Malocide
Maloprim
MCB-3837
MLS000028606
MLS001148621
MLS002454446
MLS002701881
MolPort-001-783-655
NCGC00016256-01
NCGC00016256-02
NCGC00023188-03
NCGC00023188-04
NCGC00023188-05
NCGC00023188-06
NCGC00023188-07
nchembio.215-comp13
nchembio.87-comp22
NCI60_002604
NCI-C01683
NCIOpen2_008313
NINDS_000652
NSC 3061
NSC3061
NSC-3061
Oxaquin
Pirimecidan
Pirimetamin
Pirimetamina
Pirimetamina [INN-Spanish]
Pirimetamina [Spanish]
Prestwick_504
Prestwick0_000037
Prestwick1_000037
Prestwick2_000037
Prestwick3_000037
Primethamine
Pyremethamine
Pyrimethamin
pyrimethamine
Pyrimethamine
Pyriméthamine
Pyrimethamine (JAN/USP/INN)
Pyrimethamine (Pyr)
Pyrimethamine [USAN:INN:BAN:JAN]
Pyrimethamine Hcl
Pyrimethaminum
Pyrimethaminum [INN-Latin]
RP 4753
S2006_Selleck
SAM002554921
SMR000058714
SPBio_000672
SPBio_002054
Spectrum_000906
SPECTRUM1500520
Spectrum2_000886
Spectrum3_001701
Spectrum4_000494
Spectrum5_001447
TCMDC-123831
TCMDC-125860
Tindurin
Tindurine
Tinduring
UNII-Z3614QOX8W
Wellcome brand OF pyrimethamine
Wellcome Brand of Pyrimethamine
WLN: T6N CNJ BZ DZ ER DG& F2
WR 2978
ZINC00057464
|
|
8 |
|
leucovorin |
Approved |
Phase 3 |
|
58-05-9 |
6006 143 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-formyltetrahydrofolate
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
Acid, folinic
Acide folinique
Acido folinico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
9 |
|
Triclabendazole |
Approved, Investigational |
Phase 3 |
|
68786-66-3 |
|
Synonyms:
|
10 |
|
Tranexamic Acid |
Approved |
Phase 3 |
|
1197-18-8 |
5526 |
Synonyms:
08455_FLUKA
1197-17-7
1197-18-8
1ceb
3-14-00-00868 (Beilstein Handbook Reference)
4-(aminomethyl)cyclohexane-1-carboxylic acid
4-(Aminomethyl)cyclohexanecarboxylic acid
4-(Aminomethyl)-Cyclohexanecarboxylic Acid
857653_ALDRICH
A0236
AB00052260
AB1003647
AC1L1KJH
AC1Q50F3
AC1Q546D
AC1Q5U04
AC-4687
Acide tranexamique
Acide tranéxamique
Acide tranexamique [INN-French]
acido Tranexamico
Acido tranexamico
ácido tranexámico
Acido tranexamico [INN-Spanish]
Acidum tranexamicum
Acidum tranexamicum [INN-Latin]
ALBB-006013
AMCA
AMCHA
AMH
Amikapron
Amstat
Anvitoff
AR-1F6595
BAY 3517
BPBio1_000069
BRN 2207452
BSPBio_000061
BSPBio_002837
Carxamin
CAS-1197-18-8
CHEBI:48669
CHEMBL292500
CHEMBL877
CID5526
cis-4-(Aminomethyl)cyclohexanecarboxylic acid
cis-4-Aminomethylcyclohexane-1-carboxylic acid
cis-AMCHA
CL 65336
CL-65336
Cyclocapron
Cyklokapron
Cyklokapron (TN)
D01136
DB00302
DivK1c_000655
DV 79
DV79
DV-79
EINECS 214-818-2
Emorhalt
Exacyl
Frenolyse
Hexapromin
Hexatron
HMS1568D03
HMS1921F08
HMS2092P03
HMS502A17
I04-0993
IDI1_000655
KABI 2161
KBio1_000655
KBio2_001871
KBio2_004439
KBio2_007007
KBio3_002337
KBioGR_000511
|
KBioSS_001871
LS-56611
LS-56612
LT00159441
Mastop
MolPort-001-792-390
MolPort-002-512-008
NCGC00016569-01
NCGC00016569-02
NCGC00016569-03
NCGC00094944-01
NCGC00094944-02
NINDS_000655
NSC 291305
NSC291305
Oprea1_786414
Prestwick_476
Prestwick0_000171
Prestwick1_000171
Prestwick2_000171
Prestwick3_000171
Rikavarin
Rikavarin (TN)
Rikavarin-S
RP 18,429
SPBio_000689
SPBio_001982
Spectrum_001391
SPECTRUM1502026
Spectrum2_000655
Spectrum3_001189
Spectrum4_000046
Spectrum5_001258
Spiramin
STK503668
STOCK1N-16183
t-AMCHA
Tamcha
Tranex
Tranexamate
tranexamic acid
Tranexamic acid
Tranexamic acid (JP15/USAN/INN)
Tranexamic acid [USAN:INN:BAN:JAN]
Tranexamic acid cis-form
Tranexamsaeure
Tranexan
Tranexmate
tranexmic acid
Tranexmic acid
Tranhexamate
Tranhexamic acid
trans AMCHA
Trans AMCHA
Trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid
trans-1-Aminomethylcyclohexane-4-carboxylic acid
Trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylate
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-(Aminomethyl)cyclohexane-carboxylic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylate
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-4-Aminomethylcyclohexane-1-carboxylic acid
trans-4-AMINOMETHYLCYCLOHEXANE-1-carboxylIC ACID
trans-Amcha
Transamin
Transamin (TN)
Transamlon
Trans-p-(Aminomethyl)cyclohexanecarboxylic
trans-p-(Aminomethyl)cyclohexanecarboxylic acid
trans-Tranexamate
trans-Tranexamic acid
Trasamlon
Ugurol
UNII-6T84R30KC1
WLN: L6TJ AVQ D1Z -T
|
|
11 |
|
Zinc |
Approved, Investigational |
Phase 2, Phase 3 |
|
7440-66-6 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
|
Mannosidase b, alpha
Neutral alpha mannosidase
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
12 |
|
Zinc sulfate |
Approved, Investigational |
Phase 2, Phase 3 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
13 |
|
Mefloquine |
Approved, Investigational |
Phase 3 |
|
53230-10-7 |
4046 |
Synonyms:
(-)-(11S,2'R)-erythro-Mefloquine
(-)-Mefloquine
(-)-Threo-Mefloquine
(+)-(11R,2'S)-erythro-Mefloquine
(+)-Mefloquine
(+)-Threo-Mefloquine
(DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol
(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2R)-piperidin-2-yl]methanol
(S)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2S)-piperidin-2-yl]methanol
[(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
[2,8-bis(trifluoromethyl)quinolin-4-yl]-piperidin-2-ylmethanol
49752-90-1
51688-68-7
51742-87-1
51744-84-4
51744-85-5
53230-10-7
68682-27-9
a-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
AB00052310
AC1L1HAJ
AC1L249S
AC1L9UO6
AC1MHD7J
AC1MHD7O
AC1Q4K1I
alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
alpha-2-Piperidyl-2,8-bis(trifluoromethyl)quinoline-4-methanol
AR-1G4597
BIDD:GT0596
BIDD:PXR0166
BPBio1_000190
BRD-A89585551-003-03-4
BSPBio_000172
C07633
C17H16F6N2O
CAS-51773-92-3
CHEBI:151162
CHEBI:403542
CHEMBL411329
CHEMBL411685
CHEMBL411686
CHEMBL416956
CID3000506
CID3000516
CID4046
CID40692
CID456309
D04895
DB00358
DivK1c_000790
EINECS 256-468-3
Erthro-.alpha.-[2-piperidyl]-2,8-bis[trifluoromethyl]-4-quinolinemethanol
HMS1922C09
HMS502H12
Hoffmann la roche brand OF mefloquine hydrochloride
Hoffmann-la roche brand OF mefloquine hydrochloride
HSDB 6853
IDI1_000790
KBio1_000790
KBio2_001792
KBio2_004360
KBio2_006928
KBio3_002046
|
KBioGR_001392
KBioSS_001792
Lariam
Lariam (Hydrochloride)
LS-142023
LS-187797
Mefloquin
Mefloquina
Mefloquina [INN-Spanish]
mefloquine
Mefloquine
Méfloquine
Mefloquine (USAN/INN)
Mefloquine [USAN:INN:BAN]
Mefloquine aziridine
Mefloquine HCL
Mefloquine hydrochloride
Mefloquinone
Mefloquinum
Mefloquinum [INN-Latin]
Mephloquine
MolPort-003-981-155
MQ
NCGC00016864-01
NCGC00094994-01
NCGC00094994-02
NCGC00094994-03
NCGC00094994-04
NCGC00161831-01
NCGC00161831-02
nchembio.215-comp3
nchembio.87-comp20
NINDS_000790
NSC157387
Prestwick0_000126
Prestwick1_000126
Prestwick2_000126
Prestwick3_000126
Racemic mefloquine
RO 13-7224
RO 13-7225
Ro 215998
Ro 21-5998
Ro 21-5998 (Hydrochloride)
Ro-21-5998-001
Roche brand OF mefloquine hydrochloride
RTI1169-1-1
RTI1172-1-1
RTI1173-1-1
RTI1174-1-1
RTI1188-1-1
RTI1189-1-1
SPB-80406
SPBio_001591
SPBio_002111
Spectrum_001312
SPECTRUM1503070
Spectrum2_001516
Spectrum3_000953
Spectrum4_001066
Spectrum5_001122
UNII-TML814419R
WR 142490
WR-142,490
WR-142490
WR-177,602
α-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol
|
|
14 |
|
Artesunate |
Approved, Investigational |
Phase 3 |
|
88495-63-0 |
6917864 5464098 |
Synonyms:
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate
112346-66-4
182824-33-5
252637-87-9
4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate
4-oxo-4-{[(3r,5as,6r,8as,9r,10r,12r,12ar)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
4-oxo-4-{[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}butanoic acid
83507-69-1
88495-63-0
91487-94-4
AC1L23PW
AC1L2XWW
AC1L4FU0
AC1Q5VRV
AKOS004119951
Ambap88495-63-0
Arinate
Arsumax
Arsumax (TN)
Artesunate
Artesunate (superseded RN)
Artesunate (USAN)
Artesunato
Artesunato [INN-Spanish]
Artesunatum
Artesunatum [INN-Latin]
Artesunic acid
Artsuna
AS
BB_NC-1045
Butanedioate, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, 1-[(3R,5as,6R,8as,9R,10S,12R,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-J]-1,2-benzodioxepin-10-yl] ester
Butanedioic acid, mono(decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester
C19H28O8
CHEMBL218601
CHEMBL258608
CID105031
CID11520210
CID11988384
CID156252
|
CID5464098
CID65664
CID6917864
CID9821433
CPD000466336
D02482
Dihydroartemisinine-12-alpha-succinate
Dihydroqinghaosusuccinate
dihydroqinghasu hemsuccinate
Dihydroqinghasu hemsuccinate
Dihydroqinghasu hemsuccinic acid
FT-0082543
HMS2051I14
HMS2090L16
HSDB 7458
I06-0204
LS-177760
LS-187735
Malacef
Malartin
MLS000759445
MLS001424053
MolPort-001-732-325
MolPort-006-392-384
NCI60_039350
NSC712571
Nuartez
Plasmotrim
Plasmotrin
Qinghaozhi
Quinghaosu reduced succinate ester
S2265_Selleck
SAM001246628
SM 804
SMR000466336
Sodium artesunate
STK801911
Succinyl dihydroartemisinin
UNII-60W3249T9M
WR 256283
WR-256283
|
|
15 |
|
Amodiaquine |
Approved, Investigational |
Phase 3 |
|
86-42-0 |
2165 |
Synonyms:
||SN 10,751
2aou
4-((7-Chloro-4-quinolinyl)amino)-2-((diethylamino)methyl)phenol
4-((7-Chloro-4-quinolyl)amino)-alpha-(diethylamino)-o-cresol
4-(7-Chloro-quinolin-4-ylamino)-2-diethylaminomethyl-phenol
4-[(7-Chloro-4-quinolinyl)amino]-2-[(diethylamino)methyl]phenol
4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol
4-[(7-CHLOROQUINOLIN-4-YL)AMINO]-2-[(DIETHYLAMINO)METHYL]PHENOL
5-22-10-00283 (Beilstein Handbook Reference)
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino)
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyanilino)quinoline
7-Chloro-4-(3-diethylaminomethyl-4-hydroxyphenylamino)quinoline
86-42-0
AC-13295
AC1L1D2F
AKOS000538864
Amodiachin
Amodiachinum
Amodiaquin
Amodiaquina
Amodiaquina [INN-Spanish]
amodiaquine
Amodiaquine
Amodiaquine (USAN/INN)
Amodiaquine [USAN:INN:BAN]
amodiaquine hydrochloride
Amodiaquine hydrochloride
Amodiaquine usp24
Amodiaquine USP24
AMODIAQUINE, FLAVOQUINE
Amodiaquine, ring-closed
Amodiaquinum
Amodiaquinum [INN-Latin]
BAS 00327385
Basoquin
Bio-0471
BPBio1_000306
BRN 0300962
BSPBio_000278
C07626
C20H22ClN3O
CAM-AQ 1
Cam-AQ1
|
CAM-AQ1
CAM-AQI
Camochin
Camoquin
Camoquin HCL
Camoquinal
Camoquine
CCRIS 8486
CHEBI:2674
CHEMBL682
CID2165
CPD-10889
CQA
D02922
DB00613
EINECS 201-669-3
Flavoquin
Flavoquine
HSDB 7457
Hydrochloride, amodiaquine
LS-55353
Miaquin
MLS001304065
MolPort-001-924-563
NSC 13453
NSC13453
o-Cresol, 4-[(7-chloro-4-quinolyl)amino]-.alpha.-(diethylamino)- (6CI,7CI,8CI)
Oprea1_019229
Prestwick0_000309
Prestwick1_000309
Prestwick2_000309
Prestwick3_000309
Quinoline, 7-chloro-4-[[3-[(diethylamino)methyl]-4-hydroxyphenyl]amino]-|
Roussel brand OF amodiaquine hydrochloride
S. N. 10751
SMR000718769
SN 10,751
SN 10751
SPBio_002497
Sunoquine
UNII-220236ED28
WR-002977
|
|
16 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
ácido fólico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
|
Folipac
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
17 |
|
Piperaquine |
Experimental, Investigational |
Phase 3 |
|
4085-31-8 |
5079497 |
Synonyms:
1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane
1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine)
1,3-bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
4,4'-(propane-1,3-diyldipiperazine-4,1-diyl)bis(7-chloroquinoline)
4085-31-8
5-23-03-00072 (Beilstein Handbook Reference)
7-chloro-4-[4-[3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl]piperazin-1-yl]quinoline
83764-65-2
AC1L3UA1
AC1Q3T7B
AR-1F7471
BRN 0905079
|
C29H32Cl2N6
CHEMBL303933
CID122262
FT-0082661
I06-1673
LS-142194
piperaquine
Piperaquinoline
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro- (9CI)
Quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)
ST51053186
|
|
18 |
|
Dihydroartemisinin |
Experimental, Investigational |
Phase 3 |
|
71939-50-9 |
6918483 |
Synonyms:
(3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol
[3R-(3.alpha.,5a.beta.,6.beta.,8a.beta.,9.alpha.,10.alpha.,12.beta.,12aR*)]-Decahydro-10-hydroxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4.3-j]-1,2-benzodioxepin
1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)
71939-50-9
81496-81-3
AC1L32PY
AC1L9UV6
AC-2067
Ambotz71939-50-9
Artenimol
Artenimol (INN)
beta-Dihydroartemisinin
CHEBI:207229
CHEMBL25164
CID107770
|
CID456410
CID6918483
Cotecxin
D07362
D3793
Dihydroartemisinin
Dihydroartemisinine
Dihydroqinghaosu
Dihydroquinghaosu
Dihydroquinghoasu
GNF-PF-5634
JAV-110
LS-64240
VM3352
|
|
19 |
|
Trace Elements |
|
Phase 3 |
|
|
|
20 |
|
Micronutrients |
|
Phase 3 |
|
|
|
21 |
|
Vitamins |
|
Phase 3 |
|
|
|
22 |
|
Iron Supplement |
|
Phase 3 |
|
|
|
23 |
|
Hematinics |
|
Phase 3 |
|
|
|
24 |
|
Nutrients |
|
Phase 3 |
|
|
|
25 |
|
Antiprotozoal Agents |
|
Phase 3 |
|
|
|
26 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
27 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
28 |
|
Fanasil, pyrimethamine drug combination |
|
Phase 3 |
|
|
|
29 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
30 |
|
Folic Acid Antagonists |
|
Phase 3 |
|
|
|
31 |
|
Sulfalene |
|
Phase 3 |
|
|
|
32 |
|
Folate |
|
Phase 3 |
|
|
|
33 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
34 |
|
Hemostatics |
|
Phase 3 |
|
|
|
35 |
|
Antifibrinolytic Agents |
|
Phase 3 |
|
|
|
36 |
|
Coagulants |
|
Phase 3 |
|
|
|
37 |
|
Dermatologic Agents |
|
Phase 2, Phase 3 |
|
|
|
38 |
|
Antimalarials |
|
Phase 3 |
|
|
|
39 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
40 |
|
Artemisinine |
|
Phase 3 |
|
|
|
41 |
|
Artemisinins |
|
Phase 3 |
|
|
|
42 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 1, Phase 2 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
43 |
|
Sodium citrate |
Approved, Investigational |
Phase 1, Phase 2 |
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
44 |
|
Ivermectin |
Approved, Investigational, Vet_approved |
Phase 2 |
|
70288-86-7 |
6474909 |
Synonyms:
(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside
71827-03-7
AB00513813
AC1MJ4GR
AC1N7O27
BPBio1_000322
BRD-K24652731-001-02-7
BSPBio_000292
CHEMBL341047
CID11957587
CID4330618
CID6321424
CID6419971
CID6427057
EU-0100693
FT-0082656
HMS1568O14
HMS2089M09
I 8898
I8898_SIGMA
|
Ivermectin
IVERMECTIN
Ivermectina
Ivermectine
Ivermectinum
Lopac0_000693
MK-933
MLS001333247
MLS001333248
MLS002153248
MolPort-006-394-715
NCGC00094047-01
NCGC00094047-02
NCGC00094047-03
Prestwick_516
Prestwick2_000156
Prestwick3_000156
S1351_Selleck
SMR000857211
|
|
45 |
|
Indian frankincense |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
|
|
Synonyms:
Boswellia Glabra Resin
Boswellia Serrata
Boswellia Serrata Extract
Boswellia Serrata Gum
Boswellia Serrata Gum Extract
Boswellia Serrata Preparation
Boswellia Serrata Resin
|
Boswellia Serrata Resin Extract
Boswellia Serrata Roxb. Ex Colebr. Oleo-gum-resin
Indian Frankincense Oleo-gum-resin
Indian Frankincense Resin
Indian Olibanum
Indian Olibanum Oleo-gum-resin
Indian Olibanum Resin
|
|
46 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citretten
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
47 |
|
Pyronaridine |
Investigational |
Phase 2 |
|
74847-35-1 |
5485198 |
Synonyms:
2-Methoxy-7-chloro-10-(3',5'-bis(pyrrolin-1-ylmethyl)-4'-hydroxyphenylamino)benzo(b)-1,5-naphthyridine
4-((7-Chloro-2-methoxybenzo(b)-1,5-naphthyridin-10-yl)amino)-2,6-bis(1-pyrrolidinylmethyl)phenol
4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one
4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
74847-35-1
AC1NUNYW
Benzonaphthyridine 7351
C29H32ClN5O2
CHEMBL35228
|
CID5485198
LS-177158
Malaridine
MolPort-002-507-948
Pyronaridine
pyronaridine phosphate salt
Pyronaridine phosphate salt
STK597795
STOCK5S-98760
|
|
48 |
|
Imidazole |
Experimental, Investigational |
Phase 1, Phase 2 |
|
288-32-4 |
795 |
Synonyms:
{Pyrro[b]monazole}
1,3-Diaza-2,4-cyclopentadiene
1,3-Diazole
1H-Imidazole
Al-imidazole
Cu-imidazole
Glyoxalin
Glyoxaline
Him
IMD
Imidazol
Imidazole acetate
Imidazole citrate
|
Imidazole conjugate monoacid
Imidazole monohydrochloride
Imidazole monophosphonate
Imidazole sodium
Imidazolium chloride
Iminazole
Imutex
Miazole
N,N'-1,2-ethenediylmethanimidamide
N,N'-vinyleneformamidine
pyrro(b)Monazole
pyrro[b]Monazole
|
|
49 |
|
Uric acid |
Investigational |
Phase 1, Phase 2 |
|
69-93-2 |
1175 |
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-trihydroxypurine
2,6,8-Trihydroxypurine
2,6,8-trioxopurine
2,6,8-Trioxopurine
2,6,8-trioxypurine
2,6,8-Trioxypurine
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Acid urate, ammonium
Acid urate, sodium
Acid, uric
Ammonium acid urate
Lithate
Lithic acid
Monohydrate, monosodium urate
Monohydrate, sodium urate
Monosodium urate
|
Monosodium urate monohydrate
Potassium urate
Purine-2,6,8(1H,3H,9H)-trione
Sodium acid urate
Sodium acid urate monohydrate
Sodium urate
Sodium urate monohydrate
Trioxopurine
Urate
Urate monohydrate, monosodium
Urate monohydrate, sodium
Urate, ammonium acid
Urate, monosodium
Urate, potassium
Urate, sodium
Urate, sodium acid
Uricum acidum
|
|
50 |
|
Vaccines |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 91)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana |
Unknown status |
NCT01459146 |
Phase 4 |
Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel |
2 |
Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology |
Completed |
NCT02878564 |
Phase 4 |
Praziquantel |
3 |
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil |
Completed |
NCT00403611 |
Phase 4 |
Praziquantel 60 mg/kg;Praziquantel 40 mg/kg |
4 |
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study |
Withdrawn |
NCT02734186 |
Phase 4 |
Praziquantel |
5 |
Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial |
Unknown status |
NCT03133832 |
Phase 3 |
Companion Tablet |
6 |
Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania |
Unknown status |
NCT02541708 |
Phase 3 |
Ferric carboxymaltose;Ferrous sulfate + folic acid |
7 |
Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study |
Completed |
NCT01529710 |
Phase 3 |
Myrrh |
8 |
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire |
Completed |
NCT02868385 |
Phase 3 |
4x Praziquantel;1x Praziquantel |
9 |
Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel |
Completed |
NCT01558336 |
Phase 3 |
praziquantel |
10 |
Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children |
Completed |
NCT00870649 |
Phase 3 |
|
11 |
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study |
Completed |
NCT04115072 |
Phase 2, Phase 3 |
Praziquantel 600Mg Oral Tablet x 5;Praziquantel 600Mg Oral Tablet x 1 |
12 |
Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children |
Completed |
NCT01054651 |
Phase 3 |
Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel |
13 |
Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial |
Completed |
NCT01722539 |
Phase 3 |
Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel |
14 |
Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial |
Completed |
NCT01658124 |
Phase 3 |
Tranexamic Acid;Placebo |
15 |
A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. |
Completed |
NCT01166815 |
Phase 2, Phase 3 |
|
16 |
An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) |
Recruiting |
NCT03845140 |
Phase 3 |
L-PZQ ODT;Biltricide®;L-PZQ ODT |
17 |
Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon |
Recruiting |
NCT03779347 |
Phase 3 |
Praziquantel |
18 |
A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children |
Recruiting |
NCT03893097 |
Phase 3 |
Praziquantel;Artesunate + Mefloquine |
19 |
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial |
Recruiting |
NCT03640403 |
Phase 3 |
Dihydroartemisinin-piperaquine;Artesunate-amodiaquine |
20 |
Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II |
Unknown status |
NCT01718834 |
Phase 1, Phase 2 |
|
21 |
Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. |
Completed |
NCT01901484 |
Phase 2 |
Praziquantel |
22 |
A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents |
Completed |
NCT02178748 |
Phase 2 |
|
23 |
Activity of Mefloquine Against Urinary Schistosomiasis |
Completed |
NCT01132248 |
Phase 2 |
Mefloquine;S/P |
24 |
Evaluation of the Effect of Artemisinin-based Combination Therapies on Urinary Schistosoma Haematobium When Administered for the Treatment of Malaria Co-infection |
Completed |
NCT04264130 |
Phase 2 |
Artesunate-Pyronaridine;Artemether-Lumefantrine;Artefenomel-Ferroquine |
25 |
Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial |
Completed |
NCT03799510 |
Phase 2 |
GLA-SE solution |
26 |
Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) |
Completed |
NCT02806232 |
Phase 2 |
Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT |
27 |
Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial |
Completed |
NCT03041766 |
Phase 2 |
GLA-SE solution |
28 |
S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) |
Completed |
NCT00486863 |
Phase 2 |
Praziquantel |
29 |
A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults |
Recruiting |
NCT03910972 |
Phase 1, Phase 2 |
|
30 |
Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four |
Not yet recruiting |
NCT03640377 |
Phase 2 |
Praziquantel |
31 |
Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms |
Not yet recruiting |
NCT04407507 |
Phase 2 |
Ivermectin;Placebo |
32 |
Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial |
Not yet recruiting |
NCT03924596 |
Phase 1, Phase 2 |
AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate |
33 |
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults |
Completed |
NCT03110757 |
Phase 1 |
|
34 |
A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults |
Completed |
NCT02337855 |
Phase 1 |
|
35 |
A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection |
Completed |
NCT02376582 |
Phase 1 |
|
36 |
Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis |
Completed |
NCT01512277 |
Phase 1 |
|
37 |
Praziquantel Pharmacokinetics in Pregnancy and During Lactation |
Completed |
NCT01288872 |
Phase 1 |
Praziquantel |
38 |
Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis |
Completed |
NCT01154049 |
Phase 1 |
|
39 |
Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development |
Completed |
NCT03361163 |
Phase 1 |
|
40 |
Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. |
Unknown status |
NCT01260012 |
|
|
41 |
Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas |
Unknown status |
NCT03158298 |
|
|
42 |
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial |
Unknown status |
NCT01869465 |
|
|
43 |
Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. |
Unknown status |
NCT01541631 |
|
Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole |
44 |
The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) |
Unknown status |
NCT02329314 |
|
|
45 |
ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C |
Unknown status |
NCT02826447 |
|
|
46 |
The Effect of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia |
Unknown status |
NCT03256123 |
|
|
47 |
Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya |
Completed |
NCT00463307 |
|
|
48 |
Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children |
Completed |
NCT02144389 |
|
Praziquantel (PZQ) |
49 |
Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure |
Completed |
NCT01931826 |
|
|
50 |
Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease |
Completed |
NCT00138450 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|